JBS Buying Plant-Based Supplier Vivera in $410M Deal

Vivera is Europe's third-largest plant-based food producer, gaining JBS three manufacturing units and an R&D center located in The Netherlands.


SÃO PAULO — JBS, the world's largest protein company and second-largest food producer, has entered into an agreement to purchase Vivera, Europe's third-largest plant-based food producer, for an enterprise value of $410 million. Vivera develops and produces a broad range of innovative plant-based meat replacement products Jbs Logofor major retailers in over 25 countries across Europe, with relevant market share in The Netherlands, the United Kingdom and Germany. The deal includes three manufacturing units and a research and development center located in The Netherlands.

The acquisition of Vivera strengthens and boosts JBS' global plant-based products platform. Strong growth is expected in this category throughout global markets. The deal will add a brand to JBS' portfolio that is well-established in consumer preference, strengthening the Company's focus on value-added products.

Jbs Acquires European Company To Expand Its Global Plant Based Food Platform Vivera Schapfoto 2

Vivera, currently the largest independent plant-based company in Europe, will join other JBS initiatives such as Seara's, Incrível range, a market leader in plant-based hamburgers, and Planterra, with the OZO brand in the United States.

"This acquisition is an important step to strengthen our global plant-based protein platform", said Gilberto Tomazoni, Global CEO of JBS. "Vivera will give JBS a stronghold in the plant-based sector, with technological knowledge and capacity for innovation".

To nurture its entrepreneurial spirit JBS plans to manage Vivera as a standalone business unit with its current leadership team to remain in place.

"Joining forces with JBS gives us access to significant resources and capabilities to accelerate our current strong growth trajectory and Vivera brand expansion", said Willem van Weede, CEO, Vivera.

The deal was approved by the JBS board of directors and will be concluded after approval by the antitrust authorities.

More in Capital Investment